Cargando…
Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessment of health-care cost-effectiveness is growing in importance with increases in health expenditures, sev...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089630/ https://www.ncbi.nlm.nih.gov/pubmed/25019030 http://dx.doi.org/10.1038/kisup.2013.95 |
_version_ | 1782325142136815616 |
---|---|
author | Goto, Shunsuke Komaba, Hirotaka Fukagawa, Masafumi Nishi, Shinichi |
author_facet | Goto, Shunsuke Komaba, Hirotaka Fukagawa, Masafumi Nishi, Shinichi |
author_sort | Goto, Shunsuke |
collection | PubMed |
description | Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessment of health-care cost-effectiveness is growing in importance with increases in health expenditures, several cost-effectiveness analyses for new medications such as sevelamer, lanthanum carbonate, cinacalcet hydrochloride, and paricalcitol have been conducted. The results of these analyses have stimulated discussion on the efficient use of these medications and, in some cases, have affected treatment recommendation. However, most of these studies had methodological problems, one of them being that the effectiveness of medications was estimated based on changes of surrogate parameters, such as vascular calcification or serum biochemistry values. Furthermore, even if cost-effectiveness analyses were based on a given clinical trial, the results might differ from country to country. To provide greater health benefits under limited health expenditures based on the results of cost-effectiveness analyses, it is necessary to confirm the effectiveness of medications through well-designed clinical trials having mortality as the primary end point. In addition, cost-effectiveness analyses need to be performed separately for each country. |
format | Online Article Text |
id | pubmed-4089630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40896302014-07-11 Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder Goto, Shunsuke Komaba, Hirotaka Fukagawa, Masafumi Nishi, Shinichi Kidney Int Suppl (2011) Review Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessment of health-care cost-effectiveness is growing in importance with increases in health expenditures, several cost-effectiveness analyses for new medications such as sevelamer, lanthanum carbonate, cinacalcet hydrochloride, and paricalcitol have been conducted. The results of these analyses have stimulated discussion on the efficient use of these medications and, in some cases, have affected treatment recommendation. However, most of these studies had methodological problems, one of them being that the effectiveness of medications was estimated based on changes of surrogate parameters, such as vascular calcification or serum biochemistry values. Furthermore, even if cost-effectiveness analyses were based on a given clinical trial, the results might differ from country to country. To provide greater health benefits under limited health expenditures based on the results of cost-effectiveness analyses, it is necessary to confirm the effectiveness of medications through well-designed clinical trials having mortality as the primary end point. In addition, cost-effectiveness analyses need to be performed separately for each country. Nature Publishing Group 2013-12 2013-11-27 /pmc/articles/PMC4089630/ /pubmed/25019030 http://dx.doi.org/10.1038/kisup.2013.95 Text en Copyright © 2013 International Society of Nephrology |
spellingShingle | Review Goto, Shunsuke Komaba, Hirotaka Fukagawa, Masafumi Nishi, Shinichi Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title_full | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title_fullStr | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title_full_unstemmed | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title_short | Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
title_sort | optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089630/ https://www.ncbi.nlm.nih.gov/pubmed/25019030 http://dx.doi.org/10.1038/kisup.2013.95 |
work_keys_str_mv | AT gotoshunsuke optimizingthecosteffectivenessoftreatmentforchronickidneydiseasemineralandbonedisorder AT komabahirotaka optimizingthecosteffectivenessoftreatmentforchronickidneydiseasemineralandbonedisorder AT fukagawamasafumi optimizingthecosteffectivenessoftreatmentforchronickidneydiseasemineralandbonedisorder AT nishishinichi optimizingthecosteffectivenessoftreatmentforchronickidneydiseasemineralandbonedisorder |